MTOR and metastatic melanoma: Most recent multi-omics analysis of metastatic melanoma patients identified no significant intra-tumoral molecular, immunological, or metabolic associations with serum LDH, including glycolysis, metabolism drivers, glucose metabolism, hypoxia, mTOR pathway, choline metabolism, checkpoint inhibitors expression, or genes of the adaptive and innate immune response.